{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "TVTX",
  "name": "Travere Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/TVTX/",
  "json_url": "https://orbyd.app/dossiers/TVTX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "FILSPARI's dual-indication ramp has fully re-rated the equity: at ~$56.71 (2026-07-17) TVTX trades at consensus PT ($52–58) and 4% under its 2026-06-25 ATH close of $59.03, having gone sideways for four weeks. The approval binary is spent; the next one is the ~2026-08-05 Q2 print, the first full FSGS quarter, against a Street bar the June target wave already raised.",
  "invalidation_trigger": "A weekly close below $52 breaks the July consolidation shelf and returns price into the June base, signaling the launch re-rating is round-tripping. Secondary: the ~2026-08-05 Q2 print showing FILSPARI net product revenue below the elevated post-approval ramp bar, or 2026 guidance held flat rather than raised.",
  "catalyst_date": "2026-08-05",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Trim logic here is structural (weekly close losing the breakout shelf / rising weekly structure) or thesis-based (Q2 guide/ramp disappointment), NOT an RSI overbought print — this is a binary-catalyst launch name, not a retail squeeze.",
    "Q2 2026 print estimated ~2026-08-05 (one vendor lists 2026-07-30) — confirm the dated IR press release before assuming the window; within 3 trading days of the confirmed date, no new longs.",
    "LGND (Ligand) carries a sparsentan royalty and prints Q2 in early August — its royalty-line color is a free read-through on FILSPARI units ahead of TVTX. LGND's next-session tape is the tell.",
    "Binary-catalyst archetype: exit logic here is structural (weekly close losing the consolidation shelf / AVWAP from the June ATH) or thesis-based (guide held flat, FSGS start-form deceleration), NOT an RSI overbought rule.",
    "Consensus PT is split by source: $58.36 across 15 analysts (stockanalysis) vs $52.08 across 13 (marketbeat). Price sits inside both bands — the sell-side headroom that existed in April is gone.",
    "Insiders net sellers ~$5.5M with zero open-market purchases in recent months — not a thesis-breaker on its own, but no insider confirmation of the next leg either.",
    "Rare-disease-approvals theme MATURING. Flip to SATURATED on the first in-basket ramp miss.",
    "The uncontested moat is FSGS. IgAN — the larger revenue base — is contested by Novartis Fabhalta and Vera's atacicept; watch competitive script data, not just headline FILSPARI totals."
  ],
  "body_markdown": "## Current Thesis\nThe launch worked, and the market has already paid for it. Since the 2026-04-14 full FDA approval of FILSPARI (sparsentan) for FSGS without nephrotic syndrome — the first approved therapy in the indication — the stock has run from the high-$30s to a 2026-06-25 all-time-high close of $59.03 and a $60.10 intraday high, +48.4% YTD off a $38.21 open. Since that high it has done nothing: $57.85 on 2026-07-07, $56.71 on 2026-07-17, a four-week flat range roughly 4% below the peak on a $5.27B market cap. Consensus price targets now bracket spot from both sides ($58.36 average across 15 analysts, $52.08 across 13 at another vendor), which means the three-wave sell-side mark-up cycle of April and June is finished. What remains is a single dated event: the first full FSGS-contributing quarter, expected ~2026-08-05. The narrative is intact and the fundamentals are compounding fast; the entry asymmetry that existed in April does not exist at consensus PT with the catalyst still two-plus weeks out.\n\n## Bull Case\n- **Revenue compounding at a rate the multiple has not caught**: trailing-twelve-month revenue of $536.2M, +96.0% YoY, with Q1 2026 FILSPARI net product sales of $105.2M (+88% YoY). Forward P/E of 24.0 on a company growing product revenue near triple digits is not a demanding number if the FSGS ramp behaves.\n- **Q1 2026 broke the loss trend**: EPS of $0.05 against a ($0.24) consensus — a $0.29 beat and the first profitable quarter of the launch era. The path from cash-burning specialty pharma to self-funded franchise is a re-rating vector distinct from unit growth.\n- **FSGS is uncontested**: no competing approved therapy exists for the ~30,000–40,000 US patient pool, and FILSPARI's 48% vs 27% proteinuria reduction against irbesartan in DUPLEX carries a durability read from the 2026-06-04 open-label extension, which matters for a chronic lifelong-dosing indication. Distribution is already built — the FSGS layer rides existing IgAN salesforce infrastructure at modest incremental SG&A.\n- **Patent runway extended**: the 2026-05-27 USPTO Notice of Allowance on a method-of-use claim in IgAN, plus Orange Book submission, pushes generic exposure toward the late decade on the franchise asset.\n- **Second shot on goal**: the 2026-06-02 exclusive license for Everest Medicines' civorebrutinib (BTK inhibitor) reframes the equity from single-molecule dependency toward a rare-renal platform. Undisclosed deal economics are the near-term capital-discipline check.\n- **Commercial scale-up is visible in hiring**: the 2026-07-10 inducement grants covering 41,600 shares to six new employees under Nasdaq Rule 5635(c)(4) are a small but dated signal that headcount is being added into the FSGS ramp rather than after it.\n\n## Bear Case\n- **Price sits at consensus, which is where momentum edge dies**: at $56.71 the stock trades inside every published target band and above the lower consensus average. The playbook edge is buying 1–3 weeks *before* the sell-side marks up. Here the mark-up already happened three times — April, early June, and the 06-15 through 06-25 wave (Citi $70, Evercore $60, Wedbush $61, Guggenheim $65).\n- **Four weeks of flat tape after a vertical move**: no higher high since 2026-06-25 and a lower close on 2026-07-17 than on 2026-07-07. Distribution and healthy digestion look identical until one of them resolves; there is no reason to guess which before the print.\n- **The bar into Q2 is elevated by the same analysts who raised it**: models were revised up twice on the FSGS approval. A record top line that still misses an elevated consensus caps the stock for two or three quarters — a mechanism Q1 already demonstrated at the headline line despite record product sales.\n- **IgAN, the larger revenue base, is contested**: Novartis' Fabhalta (iptacopan) is approved in IgAN and Vera Therapeutics' atacicept is advancing. FSGS gets the headlines; the majority of FILSPARI dollars still come from an indication with credible competition. Script-share erosion in IgAN would offset FSGS adds inside one headline number.\n- **No insider confirmation**: roughly $5.5M in insider sales against zero open-market purchases in recent months. Sellers at the top of a 4x 52-week range ($15.03–$60.10) is not a thesis break, but it removes one confirmation signal.\n- **Still unprofitable on a trailing basis** (net income −$21.4M ttm) with a P/B near 44 — the valuation carries no downside cushion if the ramp story stalls.\n\n## Setup & Price Structure\nSpot $56.71 (2026-07-17, +2.59% on the session). ATH close $59.03 (2026-06-25); 52-week range $15.03–$60.10. The structure is a four-week sideways shelf in roughly the $55–59 band, sitting on top of a June breakout base near $48 where the third leg launched. That is constructive consolidation for a name that quadrupled in a year, and it is also exactly the shape that precedes a failed retest. The distinguishing evidence arrives with the print, not before.\n\nEntry geometry for a fresh position is poor right now: upside to the highest published target ($70) requires a fourth mark-up wave, upside to the average is ~3%, and the downside to the June base is roughly 15%. That is not a 3:1 setup. A clean re-entry shape would be either a reclaim of the ATH on expanding volume with the print behind it, or a pullback that holds the $52 area and builds a higher low. Buying into a flat range with a binary 12 trading days out is paying for the event without the discount.\n\n## Catalyst Calendar (next 30 days)\n\n- **Early August 2026 (est.)** — Ligand Pharmaceuticals (LGND) Q2 results. LGND holds a sparsentan royalty; its royalty-line commentary typically lands before or alongside TVTX and reads through directly to FILSPARI units.\n- No FDA action dates, no PDUFA, no data readouts scheduled inside the 30-day window.\n\n## Elapsed catalysts\n\n- **~2026-08-05 (est.)** — Q2 2026 financial results and conference call. One vendor lists 2026-07-30; the dated IR press release is the confirmation. This is the first quarter with a full FSGS contribution and the only event that matters in the window. The gradeable items: FILSPARI net product revenue versus the ~$130M+ sequential step consensus implies, FSGS patient start-form and reimbursed-script counts, and whether 2026 guidance is raised or merely reaffirmed. *(passed 4d ago)*\n- **Rolling** — potential civorebrutinib development-plan disclosure or deal-economics detail following the 2026-06-02 Everest agreement. Undated, so not tradeable as a setup, but it changes the platform framing if it lands. *(passed 68d ago)*\n\n## What Would Change Our Mind\n- **Bullish flip**: a weekly close above $60.10 on expanding volume with the Q2 print already behind it, accompanied by a fourth target-revision wave taking the band above $70. That would confirm the FSGS ramp is beating the raised bar and re-open a momentum leg with the binary removed.\n- **Bearish confirmation**: a weekly close below $52 breaks the July shelf and returns price into the June base — the launch re-rating round-tripping rather than consolidating. Beneath that, $48 is the structural line where the third leg began.\n- **Fundamental break**: Q2 FILSPARI net product revenue landing below the post-approval ramp bar, 2026 guidance held flat rather than raised, or any commentary indicating FSGS start-form conversion is decelerating after the initial pent-up-demand wave.\n- **Competitive break**: IgAN script share ceding to Fabhalta or a positive atacicept regulatory step that reframes the base business as contested rather than incumbent.\n- **Theme break**: the rare-disease-approvals complex flipping from maturing to saturated on the first in-basket launch miss, which would compress the entire group's multiple regardless of TVTX-specific execution.\n\n## Correlation Notes\n- **LGND (Ligand Pharmaceuticals)** — direct economic linkage via the sparsentan royalty. The cleanest single read-through on FILSPARI units, and it often reports first. Treat LGND's post-print session as a leading signal for TVTX.\n- **VERA (Vera Therapeutics)** — atacicept in IgAN. Competitive, not correlated: good VERA regulatory news is a TVTX headwind on the base business, which makes the pair a useful divergence check rather than a confirmation.\n- **Novartis (NVS)** — Fabhalta/iptacopan is the approved IgAN competitor. Watch NVS renal-franchise disclosure for share commentary; the read is one-directional against TVTX.\n- **Rare-disease and orphan-drug complex** broadly — TVTX trades with the group's risk appetite on macro-driven biotech days, and the group is in a maturing phase where the marginal name re-rates on execution rather than on approval headlines. That regime rewards holding proven ramps and punishes paying up for a story already priced.\n- **XBI / small-cap biotech beta** — at a $5.27B cap with a 4x annual range, the name carries high sensitivity to rate-driven risk-off in the sector. A biotech-wide drawdown drags it through the July shelf independent of anything company-specific.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-07-19T11:53:52+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}